CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and olde ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Clinicians should identify barriers to treatment and improving clinical influenza testing, providing antiviral treatment for children with influenza-associated hospitalizations with >2 days of ...

Dr. Renee Wynn is a doctorally educated, board-certified Women's Health Nurse Practitioner who focuses on perinatal and reproductive health justice. She is an Assistant Professor ...

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups. Black mothers are faced with a disproportionate number of barriers ...

As long as a drug shortage is declared, compounding pharmacies are still eligible to produce their own versions of Zepbound/Mounjaro. HealthDay News — The US Food and Drug Administration re ...